Genentech Licenses Alector Brain Delivered GCase

Company Alector; Genentech (Roche) Event Type Licensing Modality Brain-delivered enzyme replacement (engineered GCase with blood-brain-barrier carrier) Asset AL050 Target GBA1 / glucocerebrosidase (GCase) Disease Area Parkinson’s disease (GBA1-associated); Gaucher disease Summary Genentech licensed worldwide rights to Alector’s preclinical AL050 program for $100 million upfront, as…